Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series

Abstract

Abstract Data from real‐world studies and clinical trials have documented the long‐term efficacy and safety of guselkumab in patients with moderate‐to‐severe psoriasis. Limited data are available on the long‐term use of guselkumab in morbidly obese individuals with severe psoriasis. Here, we present data on the outcome of three patients with class III obesity (body mass index (BMI) of ≥40 kg/m2) with severe plaque psoriasis treated with 100 mg guselkumab. At baseline, mean BMI was 46.5 ± 5.4 kg/m2 and mean PASI was 46.0 ± 18.5 and all patients were biologic naïve. After 12 weeks of guselkumab treatment, mean PASI decreased to 9.7 ± 4 and to 4.0 ± 1.7 at 28 weeks. After 1 year, two patients achieved complete remission and one patient had PASI of 6 (achieving remission by week 140). All three patients are still in complete remission. Our real‐life results in specific patients burdened with class III obesity naïve to biologic treatment show excellent long‐term psoriasis outcome with guselkumab.